A Phase 3 interventional study of Nilotinib (AMN107) and imatinib (STI571) in Gastrointestinal Stromal Tumor (GIST), sponsored by Novartis Pharmaceuticals. Completed at 165 sites in 35 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one has the largest enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 9th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2009.
This study's enrollment of 644 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 35 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2009, is one of 4 in phase 3, and was the 12th registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed diagnosis of GIST which is unresectable and/or and either:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nilotinib 400 mg twice a day
Drug: Nilotinib (AMN107)
imatinib 400 mg once daily
Drug: imatinib (STI571)
Also known as: Glivec/Gleevec
Time to Progression Free Survival (PFS)
PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: up to month 37
| Milestone | Imatinib First, Then Nilotinib | Nilotinib First, Then Imatinib |
|---|---|---|
| Started | 324 | 320 |
| Completed | 0 | 0 |
| Not completed | 324 | 320 |
| Withdrew: Patients didn't receive 1st line therapy | 3 | 4 |
| Withdrew: Adverse event | 31 | 21 |
| Withdrew: Abnormal laboratory value | 1 | 0 |
| Withdrew: Abnormal test procedure result | 2 | 2 |
| Withdrew: Withdrawal by subject | 16 | 17 |
| Withdrew: Lost to follow-up | 3 | 7 |
| Withdrew: Administrative problems | 3 | 3 |
| Withdrew: Death | 5 | 8 |
| Withdrew: Disease progression | 139 | 119 |
| Withdrew: Protocol deviation | 5 | 6 |
| Withdrew: Study terminated by sponsor | 116 | 133 |
| Milestone | Imatinib First, Then Nilotinib | Nilotinib First, Then Imatinib |
|---|---|---|
| Started | 39 | 125 |
| Completed | 0 | 0 |
| Not completed | 39 | 125 |
| Withdrew: Adverse event | 4 | 5 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Administrative problems | 2 | 0 |
| Withdrew: Death | 1 | 5 |
| Withdrew: Disease progression | 22 | 70 |
| Withdrew: Protocol deviation | 0 | 2 |
| Withdrew: Study terminated by sponsor | 3 | 37 |
PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
| months | Nilotinib | Imatinib |
|---|---|---|
| Time to Progression Free Survival (PFS) | 25.9 (0 to 32.8) | 29.7 (0 to 36.1) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | — | 80/321 (24.9%) | 291/321 (90.7%) |
| Imatinib | — | 85/316 (26.9%) | 289/316 (91.5%) |
| Crossover Nilotinib | — | 15/39 (38.5%) | 28/39 (71.8%) |
| Crossover Imatinib | — | 26/125 (20.8%) | 89/125 (71.2%) |
| Event | Nilotinib | Imatinib | Crossover Nilotinib | Crossover Imatinib |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 15/321 | 12/316 | 4/39 | 3/125 |
| AnaemiaBlood and lymphatic system disorders | 6/321 | 3/316 | 2/39 | 3/125 |
| PainGeneral disorders | 0/321 | 0/316 | 2/39 | 1/125 |
| DizzinessNervous system disorders | 0/321 | 0/316 | 2/39 | 0/125 |
| VomitingGastrointestinal disorders | 5/321 | 3/316 | 1/39 | 4/125 |
| Colonic fistulaGastrointestinal disorders | 0/321 | 0/316 | 1/39 | 0/125 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 5/321 | 5/316 | 1/39 | 0/125 |
| Intestinal obstructionGastrointestinal disorders | 4/321 | 2/316 | 1/39 | 3/125 |
| Small intestinal haemorrhageGastrointestinal disorders | 0/321 | 0/316 | 1/39 | 0/125 |
| Disease progressionGeneral disorders | 0/321 | 0/316 | 1/39 | 1/125 |
| Event | Nilotinib | Imatinib | Crossover Nilotinib | Crossover Imatinib |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 46/321 | 106/316 | 2/39 | 17/125 |
| NauseaGastrointestinal disorders | 73/321 | 105/316 | 12/39 | 20/125 |
| RashSkin and subcutaneous tissue disorders | 89/321 | 46/316 | 4/39 | 12/125 |
| Oedema peripheralGeneral disorders | 29/321 | 68/316 | 2/39 | 17/125 |
| VomitingGastrointestinal disorders | 51/321 | 65/316 | 5/39 | 10/125 |
| FatigueGeneral disorders | 66/321 | 65/316 | 7/39 | 12/125 |
| Abdominal painGastrointestinal disorders | 63/321 | 61/316 | 6/39 | 18/125 |
| HyperbilirubinaemiaHepatobiliary disorders | 63/321 | 11/316 | 3/39 | 3/125 |
| AnaemiaBlood and lymphatic system disorders | 38/321 | 61/316 | 7/39 | 20/125 |
| Periorbital oedemaEye disorders | 2/321 | 58/316 | 0/39 | 9/125 |
| Age, Continuous(years) | Imatinib First, Then Nilotinib | Nilotinib First, Then Imatinib | Total |
|---|---|---|---|
| Mean | 57.4 ± 12.91 | 57.3 ± 12.63 | 57.35 ± 12.77 |
| Sex: Female, Male(Participants) | Imatinib First, Then Nilotinib | Nilotinib First, Then Imatinib | Total |
|---|---|---|---|
| Female | 145 | 133 | 278 |
| Male | 179 | 187 | 366 |
Showing the first 100 of 165 sites across 35 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2009, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Gastrointestinal Stromal Tumors →